TO STUDY THE CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH CHRONIC SCHIZOPHRENIA WHO ARE RECEIVING TREATMENT AND NOT RECEIVING TREATMENT

Krishna Kumar Carpenter, Ujwal Sardesai, Ram Ghulam Razdan

Abstract


 Objective: To assess the cardiovascular risk in chronic schizophrenia(duration >2 yrs) patients with and without treatment.

 Materials and Methods: 100 OPD patients (aged 20 or above,both male or female), who were diagnosed with chronic schizophrenia(duration >2yrs) with and without treatment according to the International Classification of Diseases  Classification of Mental and Behavioral Disorders Diagnostic criteria for research 10th revision. Those patients were evaluated for the coronary heart disease (CHD) risk as per Framingham (10 year all CHD events) function/risk equation.

Results: Intermediate cardiovascular risk was found in 2% without treatment patients and 5.73% in with treatment patients. Compared to females, males had higher Framingham score (4.08± 4.51 vs. 1.07± 0.26, likelihood ratio= 622.19, P value < 0.05 in with treatment patients and 1.63± 1.67 vs. 1.11± 0.48,likelihood ratio= 6.444, P value > 0.05 in without  treatment patients)

 Conclusion: Patients of schizophrenia have a high prevalence of cardiovascular risk factors. Hence, there is a need to screen the patient of schizophrenia for the cardiovascular risk and manage it as early as possible.


Keywords


Cardiovascular risk, mortality, schizophrenia

Full Text:

PDF

References


(1)Carlsson A, Lindquist L. Effect of chlorpromazine or haloperidol on formation of 3- methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologica etToxicologica. 1963;20:140–145. Clementz BA, Sweeney JA, Hamm JP, et al. Identification of distinct psychosis biotypes using brain-based biomarkers. Am J Psychiatry. 2016;173:373–384. Hyman SE. Revolution stalled. Sci Transl Med. 2012;4(155):155cm11.

(2)Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010;196(2):116–121.

*Charlson FJ, Baxter AJ, Dua T, Degenhardt L, Whiteford HA, Vos T. Excess mortality from mental, neurological, and substance use disorders in the Global Burden of Disease Study 2010. In: Patel V, Chisholm D, Dua T, Laxminarayan R, Medina-Mora ME, eds. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities. 3rd ed (Volume 4). Washington (DC): The International Bank for Reconstruction

(3) Bolíbar B, Fina Avilés F, Morros R, et al.; SIDIAP Group. [SIDIAP database: electronic clinical records in primary care as a source of information for epidemiologic research]. Med Clin (Barc) 2012;138(14):61721. Spanish.

(4) Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second generation antipsychotics. Bipolar Disord 2008;10:788 97.

(5) Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al. A comparison of ten year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005;80:45 53.

(6) Bobes J, Arango C, Aranda P, Carmena R, Garcia Garcia M, Rejas J, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study. Schizophr Res 2007;90:162 73.

(7) "NHLBI, Estimate of 10-Year Risk for CHD". Nhlbi.nih.gov. Retrieved 2013-09-14.

(8)Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005;80:45-53.

(9)Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study. Schizophr Res 2007;90:162-73.

(10)Malhotra N, Grover S, Chakrabarti S, Kulhara P. Metabolic syndrome in schizophrenia. Indian J Psychol Med 2013;35:227-40

(11)Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008;105:175-87.

(12)Phutane VH, Tek C, Chwastiak L, Ratliff JC, Ozyuksel B, Woods SW, et al. Cardiovascular risk in a first-episode psychosis sample: A 'critical period'

(13) https://www.ncbi.nlm.nih.gov/pubmed/27863522

(14) Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ. 1998; 316:1043-7. [PMC free article] [PubMed] [Google Scholar]

(15) Ossewaarde ME, Bots ML, Verbeek AL, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology. 2005;16:556-62. [PubMed] [Google Scholar]


Refbacks

  • There are currently no refbacks.